REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
RGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome, if approved Commercial launch pla...